* pregnant or lactating women * patients already participating in another clinical study * oxygen saturation \< 70% (ambient) * clinical evidence of an infectious disease different from covid at the time of admission * chronic kidney failure * coronary disease * glomerular filtration rate \< 30ml/min/1.73 m2 and known history of preexisting chronic renal failure (chronic kidney disease stages 4-5) * known history of hcv, hbv and/or clinical signs of hepatic liver failure. * any type of cancer * hiv and/or any anti retroviral treatment * inability to freely decide to participate * psychotropics treatment * erythromycin treatment * polydrug use (defined as more than two addictions combined) * with transplant background * with any autoimmune disorder * with known hypersensibility to maraviroc and/or favipiravir * on invasive mechanical ventilation at the time of randomization

* pregnant or lactating women * patients already participating in another clinical study * oxygen saturation \< 70% (ambient) * clinical evidence of an infectious disease different from covid at the time of admission * chronic kidney failure * coronary disease * glomerular filtration rate \< 30ml/min/1.73 m2 and known history of preexisting chronic renal failure (chronic kidney disease stages 4-5) * known history of hcv, hbv and/or clinical signs of hepatic liver failure. * any type of cancer * hiv and/or any anti retroviral treatment * inability to freely decide to participate * psychotropics treatment * erythromycin treatment * polydrug use (defined as more than two addictions combined) * with transplant background * with any autoimmune disorder * with known hypersensibility to maraviroc and/or favipiravir * on invasive mechanical ventilation at the time of randomization

pregnant or lactating women patients already participating in another clinical study oxygen saturation < 70% (ambient) clinical evidence of an infectious disease different from covid at the time of admission chronic kidney failure coronary disease glomerular filtration rate < 30ml/min/1.73 m2 and known history of preexisting chronic renal failure (chronic kidney disease stages 4-5) known history of hcv, hbv and/or clinical signs of hepatic liver failure. any type of cancer hiv and/or any anti retroviral treatment inability to freely decide to participate psychotropics treatment erythromycin treatment polydrug use (defined as more than two addictions combined) with transplant background with any autoimmune disorder with known hypersensibility to maraviroc and/or favipiravir on invasive mechanical ventilation at the time of randomization

pregnant or lactating women patients already participating in another clinical study oxygen saturation < 70% (ambient) clinical evidence of an infectious disease different from covid at the time of admission chronic kidney failure coronary disease glomerular filtration rate < 30ml/min/1.73 m2 and known history of preexisting chronic renal failure (chronic kidney disease stages 4-5) known history of hcv, hbv and/or clinical signs of hepatic liver failure. any type of cancer hiv and/or any anti retroviral treatment inability to freely decide to participate psychotropics treatment erythromycin treatment polydrug use (defined as more than two addictions combined) with transplant background with any autoimmune disorder with known hypersensibility to maraviroc and/or favipiravir on invasive mechanical ventilation at the time of randomization

- pregnant or lactating women - patients already participating in another clinical study - clinical evidence of an infectious disease different from covid at the time of admission - signs of respiratory distress - chronic kidney failure - coronary disease - glasgow score < 13 - glomerular filtration rate < 60ml/min/1.73 m2 and known history of preexisting chronic renal failure (chronic kidney disease stages 3,4,5) - known history of hcv, hbv and/or clinical signs of hepatic liver failure. - any type of cancer - hiv and/or any anti retroviral treatment - psychotropics treatment - with transplant background - with any autoimmune disorder - with known hypersensibility to maraviroc and/or favipiravir

- pregnant or lactating women - patients already participating in another clinical study - clinical evidence of an infectious disease different from covid at the time of admission - signs of respiratory distress - chronic kidney failure - coronary disease - glasgow score < 13 - glomerular filtration rate < 60ml/min/1.73 m2 and known history of preexisting chronic renal failure (chronic kidney disease stages 3,4,5) - known history of hcv, hbv and/or clinical signs of hepatic liver failure. - any type of cancer - hiv and/or any anti retroviral treatment - psychotropics treatment - with transplant background - with any autoimmune disorder - with known hypersensibility to maraviroc and/or favipiravir